1 ORIGINAL RESEARCH

2 Zen et al

3 **A Multi-center Study of COVID-19 with Multivariate Prognostic**

4 **Analysis**

5

6 Wen Zeng^{*1}

7 Xin Feng^{*1},

8 Jie Huang^{*2}

9 Chuan Du^{*3}

10 Dongming Qu^{*4}

11 Xiang Zhang⁵

12 Jianquan Zhang¹

13 ¹ Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical
14 University, Nanning, Guangxi 530021, China

15 ²The Fourth People's Hospital of Nanning City, Nanning, Guangxi, 530021, China

16 ³Hubei No.3 People's Hospital of Jiangnan University, Wuhan, Hubei,430000, China

17 ⁴Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, 541000, China

18 ⁵Wuhan Huangpi District Hospital of Traditional Chinese Medicine, Wuhan, Hubei, 430000, China

19 * These authors contributed equally to this project and should be considered co-first authors.

20 **Correspondence:**

21 Jianquan Zhang, MD, PhD

22 Department of Respiratory and Critical Care Medicine,1 Guangxi 530021, China

23 E-mail: jqzhang2002@126.com

24 Tel.: +86 139 7812 3845

25 Fax: +86 0771 535 0031

26

27 **Abstract:**

28 **Purpose:** Coronavirus disease (COVID-19) pandemic is now a global health concern.

29 However, there is no detailed analysis of the factors related to patients' improvement.

30 **Patients and methods:** We compared the clinical characteristics, laboratory findings, CT
31 images, and treatment of COVID-19 patients from two different cities in China. One hundred
32 and sixty-nine patients were recruited from January 27 to March 17, 2020 at five hospitals in
33 Hubei and Guangxi. They were divided into four groups according to age and into two groups
34 according to presence of comorbidities. Multivariate statistical analyses were performed for
35 the prognosis of the disease.

36 **Results:** Fifty-two patients (30.8%) had comorbidities, and the percentage of critical
37 COVID-19 was higher in the comorbidities group (11.6% vs. 0.9%, $p < 0.05$). Older patients had
38 higher proportion of severe or critical disease. The results showed that lymphocyte count was
39 significantly associated with the number of days from positive COVID-19 nucleic acid test to
40 negative test; number of days from onset of symptoms to confirmation of diagnosis was
41 significantly associated with the time it took for symptoms to improve; and number of days
42 from onset of symptoms to confirmation of diagnosis and disease severity were significantly
43 associated with chest computed tomography improvement.

44 **Conclusions:** Age, comorbidities, lymphocyte count, and SpO₂ may predict the risk of severity
45 of COVID-19. Early isolation, early diagnosis, and early initiation of management can slow
46 down the progression and spread of COVID-19.

47

48 **Keywords:** COVID-19; Severity; Multiple lung lobe involvement, prognosis

Key Points: Age and comorbidities can predict the risk of severity of COVID-19, Lymphocyte count and SpO₂ may predict the risk of severity of COVID-19. Early isolation, Early diagnosis can slow down the progression of COVID-19

1.Introduction

Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), has spread throughout the world, posing a critical threat to global health. COVID-19 has been declared as a public health emergency by the World Health Organization, and 3,175,207 laboratory-confirmed infections had been reported globally by May 1, 2020.¹ Several studies have described the clinical characteristics and epidemiology of COVID-19.²⁻⁶ The novel corona virus has caused clusters of severe respiratory illness, similar to severe acute respiratory syndrome coronavirus.^{2,5} Previous studies have also summarized the early clinical, laboratory, and computed tomography (CT) findings of COVID-19 pneumonia.^{3,6} A multi-center study of clinical features showed that multiple organ dysfunction and impaired immune function were the typical characteristics of severe and critical disease, and advanced age (≥ 75 years) was a risk factor for mortality.⁴ However, there is no detailed analysis of the factors related to patients' improvement. In this study, we analyzed the clinical features, laboratory findings, CT images, outcomes, and therapies (including antiviral drugs, antibacterial drugs, and corticosteroids) in 169 COVID-19 cases from three cities (Nanning and Guilin in Guangxi Province, and Wuhan in Hubei Province). We also analyzed the factors related to patients' improvement.

71 **2.Methods**

72 2.1. Study design and participants

73 Patients who were ≥ 18 years old were recruited for this multi-center retrospective study from
 74 five hospitals designated for the treatment of COVID-19 in China, namely Guangxi Medical
 75 University First Affiliated Hospital and The Fourth People's Hospital of Nanning City, both in
 76 Nanning; Nanxishan Hospital of Guangxi Zhuang Autonomous Region, in Guilin, Guangxi
 77 Province; and Wuhan Huangpi District Hospital of Traditional Chinese Medicine and Hubei
 78 No.3 People's Hospital of Jiangnan University, both in Wuhan, Hubei Province. The
 79 recruitment period was from January 27 to March 17, 2020. All patients enrolled in this study
 80 were diagnosed with COVID-19 according to the diagnostic criteria from the Chinese Clinical
 81 Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition), which was
 82 produced by the National Health Commission of China.⁷ The study was approved by the
 83 Research Ethics Commission of Guangxi Medical University First Affiliated Hospital
 84 approval number: 2020(KY-E-06).

85 We grouped the patients according to their ages into group A (18–44 years), group B (45–64
 86 years), group C (64–74 years), and group D (>75 years). Analysis of prognosis of improvement
 87 included three aspects: number of days from positive COVID-19 nucleic acid test to negative
 88 test, number of days from onset of illness (the first day of presenting with COVID-19-related
 89 symptoms, such as fever, cough, and diarrhea) to improvement in symptoms, and improvement
 90 on the second CT scan. The primary outcomes were improvement and death.

91

92 2.2. Definitions

93 According to the Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and
94 Treatment (7th edition), COVID-19 is classified by severity into mild, moderate, severe, and
95 critical types.⁷

96

97 2.3. Data collection

98 The medical records of the recruited COVID-19 patients were reviewed and general
99 information, epidemiological data, and data on clinical presentation, laboratory tests, chest CT
100 scan findings, treatment modalities, and outcome were collected. Clinical data collection was
101 completed on March 17, 2020. Du Chuang and Huang Jie cross-checked the data. The local
102 Center for Disease Control (CDC) laboratories made definitive diagnosis of COVID-19 by
103 analyzing throat-swab specimens from the upper respiratory tract or feces. Real-time reverse
104 transcription polymerase chain reaction (RT-PCR) was used to confirm COVID-19² and
105 exclude other viral infections. All patients underwent chest CT scan. Two attending
106 radiologists were invited to interpret all chest CT scans independently, and they were blinded
107 to the clinical information of each patient. The following CT features were assessed:
108 distribution of lesions (peripheral, along the bronchi, random, or diffuse), number of lobes
109 involved (one, two or three, or four or five), shape of lesions (patchy or nodular), appearance
110 (ground-glass opacity [GGO], consolidation, or GGO with consolidation), specific focal signs
111 (vascular thickening, crazy paving pattern, and fibrosis), and extrapulmonary manifestations
112 (mediastinal and hilar lymph node enlargement, pleural effusion, or pleural thickening). In case
113 of discordance between the interpretations of the two radiologists, the opinion of a third deputy
114 chief physician radiologist was sought to reach a final decision. Data on follow-up, prognosis,

and treatment were updated on April 24, 2020.

2.4. Statistical analyses

Continuous variables were expressed as medians with interquartile ranges (IQR), and categorical variables were reported as frequencies and percentages. Differences between groups were compared using the independent samples t-test or Mann-Whitney test. The single factor analysis of variance (ANOVA) or Kruskal-Wallis H test was used, as appropriate, to compare the difference among the four groups into which patients were divided based on severity of the disease. Least significant difference (LSD) or Dunn's test was used for post hoc comparisons. Categorical data were analyzed either with Pearson Chi-square test or with Fisher's exact test. Two-tailed tests were performed to determine statistical significance at the 5% level. Bonferroni correction was used for pairwise comparison.

Univariable and multivariable analyses for factors associated with the time for nucleic acid test to turn negative and the time of improvement of symptoms were performed with multiple linear regression analyses. Univariable and multivariable analyses for factors that are associated with chest CT improvement were done with Kaplan-Meier method and Cox proportional hazards regression model. Univariable and multivariable analyses for risk factors for disease severity and the relationship between age and disease severity were performed with logistic regression analyses. All data analyses were carried out using IBM Statistical Package for the Social Sciences for Windows, version 25 (SPSS Inc., Chicago, Illinois), and graphs were created using GraphPad Prism 7.0 software (GraphPad Software Inc., San Diego, CA, USA). P value less than 0.05 was considered statistically significant.

3. Results

The median age of the patients was 52.8 years (IQR, 19–82). Male patients accounted for 46.7% of all patients. Based on severity, 12 patients (7.1%) had mild COVID-19, 137 (81.1%) patients had moderate type, 13 (7.7%) patients had severe type, and 7 (4.1%) patients had critical type. The median number of days from the onset of illness to admission was 11.6 days (IQR, 18–92). Fifty-two patients had comorbidities, including hypertension, cardiovascular disease, diabetes, malignancy, cerebrovascular disease, chronic obstructive pulmonary disease (chronic obstructive pulmonary disease), chronic nephropathy, immunosuppression, and others. The most common morbidity was hypertension (17.8%). Clinical symptoms included fever, cough, sputum production, dry cough, pharyngalgia, shortness of breath, hemoptysis, myalgia, digestive symptoms, hypodynamia, and others. Fever was the most common symptom (76.9%), followed by dry cough (68%). Among the 169 patients, the lymphocyte count was decreased in 111 (65.68%) patients (median=1.24 (IQR=0.18–4.11) $\times 10^9/L$). C-reactive protein (CRP) increased in 102 (65.39%) patients, lactate dehydrogenase (LDH) increased in 52 (33.33%) patients, and D-dimer increased in 55 (35.95%) patients. Alanine transaminase or aspartate aminotransferase was elevated in 56 patients (33.17%). Serum creatinine was elevated in 5 patients (2.96%), 4 patients had chronic nephropathy, and 1 patient's renal function returned to normal after treatment. One hundred and fifty-four (90.1%) patients received antiviral therapy within the first 3 days. Antivirals used included lopinavir, tonavir, abidor, ribavirin, ganciclovir, and oseltamivir. Most patients (53.9%) received antibacterial therapy, including moxifloxacin, cephalosporins, and azithromycin. Forty-eight (28.4%) patients received corticosteroids. One hundred and sixty-five (97.60%) patients improved, while four patients died.

Among the 169 patients, 121 were from hospitals in Wuhan, while 48 were from hospitals in Guangxi. We compared the clinical data between the two groups. The Guangxi group had fewer days from onset of illness to admission (5.24:14.09) ($p<0.05$). Cough and sputum production were more common in the Wuhan group ($p<0.05$). The total protein and albumin in patients from Wuhan group were lower, while LDH was higher ($p<0.05$). The four patients who died were all in Wuhan group (Table 1).

Among the 4 age groups into which patients were stratified, groups C and D had higher proportions of severe and critical disease than the other 2 groups, and group C had the highest proportion of severe disease among the 4 groups. Group A had the least proportion of patients with dyspnea, while group C had the highest. In both group C and group D, oxygen saturation (SpO_2) was lower than 94%, and group C had the lowest SpO_2 . The lymphocyte count was lower in groups C and D than in groups A and B. LDH in group A was the lowest. CRP, pro-calcitonin (PCT), and interleukin (IL)-6 were significantly higher in groups C and D than in groups A and B. (Table 2).

Fifty-two patients (30.8%) in the study had comorbidities. Compared with patients who had no comorbidities, the percentage of critical COVID-19 was higher in the comorbidities group (11.6% vs. 0.9%; $p<0.05$). Patients with comorbidities were also more likely to have dyspnea (36.5% vs. 16.2%; $p<0.05$). The total protein and albumin values and lymphocyte counts in patients with comorbidities were lower, while increase in CRP and LDH was more obvious in this group. All 4 patients who died had comorbidities (Table 3).

To determine the association of disease severity with age, we divided all patients into 5 groups at intervals of 15 years, and analyzed the frequencies of severe and critical disease. We found

that older patients had higher proportion of severe or critical disease(Table 4).The 169 patients were also divided into two groups—mild group(including mild type and moderate type COVID-19,n=148) and severe group(including severe and critical type COVID-19, n=21)—and we then analyzed the risk factors for disease severity. The results showed that lymphocyte count and SpO₂ at admission were factors that determined the risk factor of disease severity (Table5).

A total of 116 patients with CT image data were enrolled in this study. The average time from onset of illness to CT imaging was 10.73 ± 7.97 (0–34) days. The first CT imaging findings of the 116 patients were analyzed, and we found that 84(72.41%) patients had bilateral lung involvement,88(75.86%) patients hadperipheral lesions, and99(85.3%) patients had involvement of two or more lung lobes. The most common CT features were consolidation (66.4%), GGO (55.2%), linear opacity (55.20%), and mixed GGO and consolidation (33.60%). Forty (34.48%) patients had vascular thickening.

We further divided the patients into 6 groups according to the number of days from onset of illness to repeat chest CT imaging: group1(≤ 7 days, n=59), group2(8–14days, n=92), group3(15–21days, n=109), group4(22–28days, n=60), group5(29–45days, n=52), and group6(46–60days, n=18). Among the groups, group 1 had the highest percentage of GGO (48cases,81.4%), and the least percentage of linear opacity (20cases, 33.9%). Group 2 had the highest percentage of consolidation (72cases,78.3%). The proportion of cases with linear opacity gradually increased from group1 to group6, reaching 98.1% in group6.There were 4casesof reticular changes in group1,and the proportion gradually increased to group 6, in which there were 7cases(Table 6).

To monitor the changes in CT images during the course of the disease, we considered the dynamic changes in the CT images of two patients from Guangxi, from onset to improvement of the disease: one with severe disease (patient1, Figure1) and the other with moderate disease (patient 2, Figure 2). As shown in Figure 1, patient 1 had ground glass opacity on chest CT in the early stage of the disease, and consolidation was noted on chest CT done on day 13 from onset of illness, as the patient's clinical symptoms improved. Consolidation had resolved on day 18 from onset of illness. Finally, the patient had linear opacity on day 23 from onset of illness. There were fifty-one patients when their clinical symptoms improved and they had checked chest CT (no more than 1 day before and after). Among them, the first CT findings were mainly GGO in 36 cases. When their clinical symptoms improved, 16 cases (44.4%) showed resolution of ground glass opacities but increased consolidation on repeat CT imaging, while 16 cases (44.4%) showed both GGO and resolution of consolidation.

All 169 patients had positive real-time RT-PCR for COVID-19 nucleic acid on nasopharyngeal swab specimens. Twenty-five patients underwent nucleic acid test on stool samples: seven of them were positive, and six among them had diarrhea. Twenty patients underwent nucleic acid test of urine samples: one was positive, but he did not have symptoms of urinary tract infection. Vaginal secretions and semen tests were performed in 6 patients, all of which were negative.

We designed three prognostic models: model 1 was based on number of days from positive COVID-19 nucleic acid test to negative test, model 2 was based on number of days from onset of illness to improvement in symptoms, and model 3 was based on whether the second CT scan was better than the first. There were 79 cases included in model 1, and multivariable analysis showed that lymphocyte count was significantly associated with the number of independent

risk factor of days for positive COVID-19 nucleic acid test to become negative (Table 7, Figure 3). There were 53 cases included in model 2, and multivariable analysis showed that number of days from onset of illness to confirmation of diagnosis was significantly associated with an independent risk factor of the time it took for symptoms to improve (Table 8, Figure 4). The average number of days from the first CT scan to the second CT scan was 5.35 days, and we took 6 days as the time point for evaluating whether the CT scans improved or not. A total of 62 patients were included in model 3, and multivariable analysis showed that number of days from onset of illness to confirmation of diagnosis and disease severity were significantly associated with independent risk factors of chest CT improvement (Table 9).

4. Discussion

This study summarizes the clinical characteristics, laboratory findings, dynamic changes in CT images, treatment, and prognosis of 169 COVID-19 patients from 5 hospitals in a western China city and in the city of disease onset, Wuhan. The study included mostly mild cases of COVID-19, which accounted for 88.2%. We analyzed the disease progression in three ways: number of days from positive COVID-19 nucleic acid test to negative test, number of days from onset of illness to improvement in symptoms, and improvement in second CT scan compared to the first. At present, no similar large sample data has been reported.

The study showed that the common symptoms of COVID-19 were fever, cough, sputum production, dyspnea, diarrhea, and myalgia. The main abnormalities in laboratory tests included that lymphocytopenia and increase in levels of CRP, LDH, and D-dimer, while PCT was normal. These findings are consistent with other literature reports.^{4,5,8,9} The most common comorbidities were hypertension, cardiovascular disease, and diabetes. Chronic

obstructive pulmonary disease was rare. Both clinical symptoms and laboratory tests indicated that patients with comorbidities had worse course of the disease, with higher proportion of severe or critical disease and poorer prognosis. Patients with comorbidities manifested with more dyspnea, lower lymphocyte count, and higher LDH, compared with those who had no comorbidities. These were manifestations of COVID-19 disease, rather than worsening symptoms of the comorbidities due to infection with SARS-Cov-2. We also found that the proportion of critical type COVID-19 increased with age. Lower lymphocyte count and SpO₂ were found in a higher proportion of patients with severe or critical type. These findings suggest that healthcare providers should pay particular attention to age, comorbidities, lymphocyte count, and SpO₂ in the diagnosis and treatment of COVID-19. These factors may predict the progression of the patient from moderate to severe or critical type.

Early CT findings showed that the lung lesions were mainly bilateral, mainly involved two or more lobes, and were mainly distributed in the peripheral zones of the lung. GGO, consolidation and mixed GGO and consolidation were the most common CT findings, while pleural effusion was rare. This is also consistent with previous literature reports.¹⁰ Through statistical analysis of lung CT imaging on different days in the course of the disease, we found the following progression: the early CT finding was GGO (1–7 days); the GGO lesion resolved or gradually evolved into consolidation shadow (1–2 weeks); consolidation resolved (2–3 weeks); then, linear opacity or reticular changes developed (4–6 weeks). The whole course took about a month. In the statistical analysis of the correlation between symptom improvement and pulmonary imaging changes in 36 patients, nearly half of the patients (16/36) showed resolution of GGO lesions and aggravation of consolidation lesions when the clinical

symptoms improved. Histological Lung biopsy specimen showed interstitial mononuclear inflammatory infiltrates (dominated by lymphocytes), diffuse alveolar damage with cellular fibro-myxoid exudate, or hyaline membrane formation.¹¹ This is different from what is seen in bacterial pneumonia. Therefore, the change in extent of GGO lesions can be used to predict the outcome of the disease, while consolidation shadow should not be used as a prognostic factor for the patients' condition.

In this study, all patients had positive nucleic acid tests for pharyngeal swabs. Seven cases had positive nucleic acid test for stool samples, but only six cases had diarrhea. One patient tested positive for urine nucleic acid test, which is a rare report at present, and may suggest that SARS-Cov-2 may cause urinary tract infection.

Most of the patients in this study were treated with antiviral drugs, including lopinavir and tonavir. Currently, there are no research data that show that such drugs have a clear effect on COVID-19. In this study, we found that the lower the lymphocyte count, the more the number of days for nucleic acid test to change from positive to negative. The longer the duration from onset of illness to admission, the longer the duration before improvement of symptoms, and the shorter the duration from onset of illness to admission, the shorter the duration for CT image improvement. Comparing patients in Hubei and Guangxi, we found that patients from Hubei had more severe disease and more days from onset of illness to admission than those from Guangxi. All of these findings suggest that early isolation, early diagnosis, and early initiation of management can contribute to slowing down the progression and spread of COVID-19.

The present study has some limitations. First, due to the limited number of cases, some results need to be further validated with more patients. Second, the effect of antiviral agents

and corticosteroidson COVID-19 needs further validation. Prospective studies should be performed to get more accurate results. Third, because this was a retrospective analysis, the time of CT imaging and nucleic acid test was not standardized and unified, t may have reduced the accuracy of the result. More cases need to be analyzed to obtain more information.

5.Conclusions

In this study, we found that older patients and patients with comorbiditieshad higher proportion of severe or critical type COVID-19. Lymphocyte count and and SpO2 at admission were associated with disease severity. Early isolation, early diagnosis, and early initiation of management can contribute to slowing down the progression and spread ofCOVID-19. These findings will be helpful for the diagnosis and treatment of COVID-19.

Funding

This research received no external funding.

Disclosure

The authors declare no conflicts of interest associated with this manuscript.

Author Contributions

WZ made substantial contributions to the conception and design of the study; acquisition, analysis, and interpretation of the data; and drafting of the manuscript. XF, JH, CD and DQ made substantial contributions to the conception and design of the study; acquisition, analysis, and interpretation of the data; and critical revision of the manuscript for important intellectual content. XZ and JZ also gave final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the

accuracy and integrity of any part of the work are appropriately investigated and resolved. JZ gave final approval of the version to be published. WZ and XF participated in analysis and interpretation of the data and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. WZ and JZ conceived of the study, participated in its design, and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank the three radiologists, Drs. Yanyan Shen, Peng Peng, Dong Deng, who helped with the analysis and interpretation of the imaging data.

Ethical approval

This study was approved by the ethics committee associated with the Faculty of Medicine at The First Affiliated Hospital of Guangxi Medical University[2020(KY-E-06)]. Informed consent was done appropriately for subjects.

References

1. World Health Organization. Situation Report-102. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200501-covid-19-sitrep.pdf?sfvrsn=742f4a18_4. Accessed May 1, 2020.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:496. doi: 10.1016/S0140-6736(20)30252-X.
3. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of coronavirus disease 2019 (COVID-19) pneumonia. *Am J Roentgenol* 2020;1-6. doi: 10.2214/AJR.20.22961.
4. Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. *Am J*

334 Respir Crit Care Med 2020;201:1380-8.

335 5.Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel
336 coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13.doi:
337 10.1016/S0140-6736(20)30211-7.

338 6.Rong W, Lingli X, Peng D, Fan H, Song M. Clinical characteristics of 96 hospitalized patients with
339 coronavirus disease 2019.Chin J Respir Crit Care Med 2020;19:144-7.

340 7. China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and
341 Treatment (7th edition). Available at: <http://kify.meetingchina.org/msite/news/show/cn/3337.html>. Accessed on
342 April 1, 2020.

343 8.Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for
344 fighting the storm. Eur J Clin Invest2020;50:e13209.doi: 10.1111/eci.13209.

345 9.Holshue ML, Debolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J
346 Med2020;382:929-36.doi: 10.1056/NEJMoa2001191.

347 10.Li B, Li X, Wang Y, et al. Diagnostic value and key features of computed tomography in coronavirus disease
348 2019.Emerg Microbes Infect2020; 9:787-93.doi: 10.1080/22221751.2020.1750307.

349 11.Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress
350 syndrome. Lancet Respir Med2020;8:420-2.doi: 10.1016/S2213-2600(20)30076-X.

351

352

353

354

355

Table1: Clinical features of study subjects in different locations

Characteristics	All (n=169)	Locations		p value
		Wuhan(n=121)	Guangxi(n=48)	
Median age (IQR) - yrs	52.8 (18–92)	53.9 (25–92)	47.9 (18–85)	0.027
Sex - no./total no.(%)				0.881
Male	79/169 (46.7)	57/121 (47.1)	22/48 (45.8)	-
Female	90/169 (53.3)	64/121 (52.9)	26/48 (54.2)	-
Disease Severity- no./total no.(%)				0.073
Mild	12/169 (7.1)	5/121 (4.1)	7/48 (14.6)	-
Moderate	137/169 (81.1)	103/121 (85.1)	34/48 (70.8)	-
Severe	13/169 (7.7)	8/121 (6.6)	5/48 (10.4)	-
Critical	7/169 (4.1)	5/121 (4.1)	2/48 (4.2)	-
Days from onset of illness to admission - median days (IQR)	11.66 (0–45)	14.09 (0–45)	5.24 (1–20)	<0.001
Symptoms - no./total no.(%)				
Fever	130/169 (76.9)	96/121 (79.3)	34/48 (70.8)	0.237
Dry cough	115/169 (68)	88/121 (72.7)	27/48 (56.3)	0.038

Sputum production	46/169 (27.4)	45/121 (37.5)	1/48 (2.1)	<0.001
Shortness of breath	38/169 (22.5)	31/121 (25.6)	7/48 (14.6)	0.121
Myalgia	15/169 (8.9)	14/121 (11.6)	1/48 (2.1)	0.070
Digestive symptoms	29/169 (17.3)	22/121 (18.3)	7/48 (14.6)	0.576
Comorbidities- no./total no. (%)				
Any comorbidity	52/169 (30.8)	40/121 (33.1)	12/48 (25.0)	0.306
Hypertension	30/169 (17.8)	23/121 (19.0)	7/48 (14.6)	0.497
Cardiovascular disease	14/169 (8.3)	11/121 (9.1)	3/48 (6.3)	0.759
Diabetes	11/169 (6.5)	10/121 (8.3)	1/48 (2.1)	0.183
Malignancy	1/169 (0.6)	1/121 (0.8)	0/48 (0)	1.000
Cerebrovascular disease	5/169 (3.0)	5/121 (4.1)	0/48 (0)	0.323
COPD or chronic bronchitis	4/169 (2.4)	4/121 (3.3)	0/48 (0)	0.579
Others	10/169 (5.9)	9/121 (7.4)	1/48 (2.1)	0.285
Laboratory findings- median (IQR)				
SpO₂-%	95.73			
	(70–100)	95.72 (70–100)	96 (87–100)	0.364
Total protein - g/L	68.69			
	(36.7–98.0)	66.68 (36.7–98.0)	73.62 (54.7–86.3)	<0.001
Albumin - g/L	38.8(18–53.8)	37.78 (18–53.8)	41.19 (24.6–53.0)	0.004
Globulin - g/L	29.86			
	(9.8–54.5)	28.87 (9.8–47.2)	32.38 (23.0–54.5)	0.002
Total bilirubin - μmol/L	12.72			
	(2.7–62.0)	14.13 (5.8–49.2)	9.88 (2.7–62.0)	0.011
ALT-U/L	44.62	49.98 (2.0–547.7)	30.46 (18.0–65.2)	0.006

	(2.0–574.7)			
AST-U/L	42.83			
	(5.0–584.0)	47.79 (9.0–584)	29.74 (5.0–72.8)	0.007
GGT-U/L	78.24 (7–906)	74.69 (7–906)	130.3 (9–601)	0.585
Creatinine - µmol/L	73.4			
	(34.5–359)	75.88 (39–359)	68.2 (34.5–245)	0.276
White blood cell count - ×10 ⁹ /L	7.07(1.01–65)	7.18 (1.01–65)	6.77 (2.3–19.4)	0.731
Neutrophilcount - ×10 ⁹ /L	5.12			
	(0.52–55.6)	5.17 (0.52–55.6)	5 (0.8–17.6)	0.862
lymphocyte cell count - ×10 ⁹ /L	1.24			
	(0.18–4.11)	1.26 (0.18–4.11)	1.18 (0.20–2.40)	0.454
Hemoglobin - g/L	130.51			
	(84–230)	130.39 (84–230)	131.13 (96–219)	0.873
Platelet count - ×10 ⁹ /L	222.35			
	(55–564)	219.12 (55–538)	238.78 (119–564)	0.328
C-reactive protein - mg/L	33.77	31.19		
	(0.04–285)	(0.04–254.35)	40.05 (0.5–285)	0.316
PCT - µg/mL	0.35			
	(0.02–6.02)	0.37 (0.02–6.02)	0.29 (0.02–2.94)	0.468
LDH - U/L	263.16			
	(120–808)	281.56 (120–808)	227.65 (151–610)	0.009
Creatine kinase - U/L	107.53			
	(12–1381)	110.94 (28–1381)	101.81 (12–355)	0.745
CK-MB - U/L	13.91 (1–73)	13.02 (4–45.7)	15.12 (1–73)	0.305
PT-s	14.65			
	(9.7–100)	15.43 (9.7–100)	13.09 (10.5–17)	0.081
D-dimer - µg/ml	2.16 (0–89)	2.7 (0–89)	0.76 (0.02–20.58)	0.292
Treatment- no./total				

no. (%)				
Antiviral	91/169(53.85)	73 (60.30)	18 (37.50)	0.007
Antibiotics	154/169	108 (89.30)	46 (95.80)	0.291
	(91.10)			
Corticosteroids	48/169(28.40)	42 (34.70)	6 (12.50)	0.004
Outcome- no./total no.				0.561
(%)				
Improvement	165/169	117/121 (96.70)	48/48 (100)	
	(97.60)			
Death	4/169 (2.40)	4/121 (3.30)	0/48 (0)	

IQR=interquartile range, COPD=chronic obstructive pulmonary disease, ALT=alanine transaminase, AST=aspartate aminotransferase, GGT=gamma glutamyl transferase, PCT=procalcitonin, LDH=lactate dehydrogenase, CK-MB=creatin kinase-MB, PT=prothrombin time

380

381

382

383

384

385 **Table2: Clinical features of study subjects according to age group**

	Age –yrs				p value
	Group A 18–44 (n=52)	Group B 45–64 (n=70)	Group C 65–74 (n=35)	Group D ≥75 (n=12)	
Sex - no./total no.(%)					0.743
Male	21/52 (40.4)	35/70 (50.0)	17/35 (48.6)	6/12 (50.0)	
Female	31/52 (59.6)	35/70 (50.0)	18/35 (51.4)	6/12 (50.0)	
Disease severity- no./total no.(%)					0.002
Mild	8/52 (15.4)	3/70 (4.2)	1/35 (2.9)	0/12 (0)	0.077
Moderate	41/52 (78.8)	63/70 (90)	24/35 (68.6)	9/12(75.0)	0.054
Severe	3/52 (5.8)	2/70 (2.9)	7/35 (20.0) ^{AC}	1/12(8.3)	0.015
Critical	0/52 (0)	2/70 (2.9)	3/35 (8.5)	2/12(16.7) ^{AD,BD}	0.020
No. of days from illness onset to admission – median(IQR)	8.2 (0–32)	14.4 (1–40) ^{AB}	12.3 (1–45) ^{AC}	9.5 (0–20)	0.009
Symptoms - no./total no.(%)					
Fever	34/52 (65.4)	60/70 (85.7)	27/35 (77.1)	9/12 (75.0)	0.073
Dry cough	33/52 (63.5)	46/70 (65.7)	26/35 (74.3)	10/12 (83.3)	0.459

Sputum production	10/52 (19.2)	22/70 (31.9)	11/35 (31.4)	3/12 (25)	0.43
Shortness of breath	3/52 (5.8)	14/70 (20.0) ^{AB}	17/35 (48.6) ^{AC}	4/12 (33.3) ^{AD}	<0.001
Myalgia	2/52 (3.8)	8/70 (22.4)	4/35 (11.4)	1/12 (8.3)	0.395
Digestive symptoms	9/52 (17.3)	11/70 (15.7)	7/35 (20)	2/12 (16.7)	0.944
Comorbidities - no./total no.(%)					
Any comorbidity	6/52 (11.5)	21/70 (30)	19/35 (54.3)	6/12 (50.0)	<0.001
Hypertension	3/52 (5.8)	10/70 (14.3)	12/35 (34.3)	5/12 (41.7)	0.001
Cardiovascular disease	2/52 (3.8)	7/70 (10.0)	5/35 (14.3)	0/12 (0)	0.257
Diabetes	0/52 (0)	2/70 (2.9)	8/35 (22.9)	1/12 (8.3)	<0.001
Malignancy	0/52 (0)	0/70 (0)	1/35 (2.9)	0/12 (0)	0.278
Cerebrovascular disease	0/52 (0)	0/70 (0)	1/35 (2.9)	4/12 (33.3)	<0.001
COPD	0/52 (0)	0/70 (0)	3/35 (8.5)	1/12 (8.3)	0.006
Others	2/52 (3.8)	5/70 (7.1)	2/35 (5.7)	1/12 (8.3)	0.825
Laboratory findings- median (IQR)					

SpO ₂ -%	97.31 (93–100)	96.17 (70–99)	93.26 (76–98)	93.55 (80–98)	0.032
Total protein - g/L	73 (57–86.3)	68.5 (36.7–98) ^{AB}	63.5 (53.4–82.2) ^{AC,BC}	65.7 (51–81.8) ^{AD}	<0.001
Albumin - g/L	43.3 (32.6–53)	38.6 (18–53.8)	33.3 (20–44.5)	36.1 (27–44)	<0.001
Globulin - g/L	29.7 (22–39.7)	29.9 (9.8–47.2)	30 (19–54.5)	29.5 (18–41.8)	0.947
Total bilirubin - μmol/L	11.9 (2.91–49.2)	11.5 (2.8–33)	12.8 (2.7–48)	20.5 (5.9–62)	0.151
ALT-U/L	45 (7–547.7)	50.4 (11–479)	32.3 (10–81)	41.5 (2–101)	0.626
AST-U/L	35.1 (9–352.7)	49.2 (13–584)	38.1 (5–157)	51.6 (20–109.2)	0.540
GGT-U/L	93.5 (10–906)	82.2 (8–527)	72.8 (7–601)	44 (7–906)	0.766
Creatinine - μmol/L	61 (34.5–91)	74.2 (41–241)	78 (46.1–245)	104.5 (60–359)	0.001
White blood cell count - ×10 ⁹ /L	6.78 (2.3–60.9)	7.46 (2.34–65)	7.1 (1.01–19.4)	5.9 (1.92–13.61)	0.893
Neutrophil count - ×10 ⁹ /L	4.76 (0.8–55.6)	5.2 (1.12–20.71)	5.62 (0.52–17.6)	5.1 (1.03–10.66)	0.91
Lymphocyte count - ×10 ⁹ /L	1.43(0.43–3.3)	1.31(0.23–4.11)	0.94(0.18–2.2) ^{AC,BC}	0.85(0.2–2.07) ^{AD,BD}	0.001
Hemoglobin - g/L	137.47 (102–230)	131.48 (100–191)	123.5 (84–177)	114.72 (87–147)	0.001
Platelet count - ×10 ⁹ /L	218.5 (55–431)	225.73 (84–564)	243 (100–538)	167.36 (85–250)	0.108

C-reactive protein - mg/L	17.76 (0.04–78.95)	30.11 (0.4–149.68)	46.84 (0.4–285)	88.57 (1–254.35)	0.006
PCT -µg/mL	0.21 (0.02–0.67)	0.34 (0.04–2.57)	0.49 (0.03–6.02)	0.56 (0.08–2.05)	0.017
LDH - U/L	212.86 (120–681)	275.74 (123–686)^{AB}	282.2 (175–544)^{AC}	369.09 (177–808)^{AD}	<0.001
Creatinekinase - U/L	117.42 (31.4–1381)	101.87 (28–355)	88.87 (12–216)	120.6 (43–600)	0.891
CK-MB - U/L	14.09 (5–68)	12.75 (4–45.7)	17.34 (6–73)	16.52 (5–32.26)	0.405
PT-s	0.24 (0.01–1.23)	0.88 (0–7.8)	4.23 (0.02–80)	10.66 (0.18–89)^{AD,BD,CD}	<0.001
D-dimer - µg/ml	13.16 (9.7–15.8)	13.37 (9.7–29.3)	15.57 (10.9–76)	21.87 (12.6–100)^{AD,BD}	0.001
Immunology – median (IQR)					
IgG- g/L	11.53 (7.84–15.16)	13.39 (7.42–20.81)	12.66 (7.96–16.69)	12.75 (7.24–19.18)	0.647
IgA- g/L	2.15 (1.32–3.44)	2.63 (1.37–5.09)	2.07 (1.47–3.34)	2.65 (2.38–4.71)	0.26
IgM- g/L	1.42 (0.64–2.29)	1.53 (0.64–3.15)	1.37 (0.82–2.55)	1.18 (0.38–2.49)	0.662
IgE- g/L	74.77 (2.4–480.1)	124.38 (1.3–1100)	32.85 (0.8–76.1)	154.15 (2.8–1008)	0.717
IL-6- pg/mL	1.69 (15–2.84)	6.76 (1.5–42.53)	33.57 (1.5–223.81)	71.34 (2.89–252.7)	0.007
C3- g/L	0.94 (0.8–1.3)	0.94 (0.6–1.3)	0.85 (0.8–1)	0.94 (0.6–1.4)	0.701

C4- g/L	0.199 (0.1–0.4)	0.18 (0.1–0.3)	0.18 (0.1–0.2)	0.22 (0.1–0.4)	0.61
CD3+ cell count - cell/μl	1057.83 (243–1736)	785.66(377–1357)	577.28(142–1310)	–	0.015
CD4+ cell count - cell/μl	666.77(79–1320)	520.5(207–1000)	402.57(79–883)	–	0.081
CD8+ cell count - cell/μl	391.05(107–892)	265.16(75–548)	174.71(58–427)	–	0.011
CD4+ cell percentage - %	–	45.87 (42.32–50.93)	39.85 (10.83–59.3)	31.23	0.546
CD8+ cell percentage - %	–	24.77 (22.08–28.67)	26.18 (14.67–46.04)	15.54	0.436
CD3+ cell percentage - %	–	72.84 (70.68–74.79)	68.87 (58.64–86.66)	47.77	0.195
NK cell percentage - %	–	5.18 (3.54–6.47)	11.71 (2.69–27.59)	7.64	0.346
Number of lung lobes involved - no./total no.(%)					
5	12/45 (26.7)	29/48 (60.4)	16/25 (64.0)	5/10 (50.0)	0.003
4	2/45 (4.5)	7/48 (14.6)	2/25 (8.0)	0/10 (0)	0.336
3	3/45 (6.7)	4/48 (8.3)	4/25 (16.0)	4/10 (4.0)	0.032
2	11/45 (24.4)	4/48 (8.3)	2/25 (8.0)	0/10 (0)	0.073
1	11/45 (24.4)	2/48 (4.2)	0/25 (0)	1/10 (10.0)	0.003

0	6/45 (13.3)	2/48 (4.2)	1/25 (4.0)	0/10 (0)	0.343
Treatment - no./total no.(%)					
Antiviral	21/52 (40.4)	39/70 (55.7)	25/35 (71.4)	6/12 (50.0)	0.047
Antibiotics	48/52 (92.3)	66/70 (94.3)	32/35 (91.4)	8/12 (66.7)	0.001
Corticosteroids	6/52 (11.5)	19/70 (27.1)	18/35 (51.4)	0/12 (0)	0.001
Prognosis - no./total no.(%)					0.24
Death	0/52 (0)	2/70 (2.9)	1/35 (2.9)	1/12 (8.3)	
improve	52/52 (100.0)	68/70 (97.1)	34/35 (97.1)	11/12 (91.7)	

IQR=interquartile range, COPD=chronic obstructive pulmonary disease, ALT=alanine transaminase, AST=aspartate aminotransferase, GGT=gamma glutamyl transferase, PCT=procalcitonin, LDH=lactate dehydrogenase, CK-MB=creatin kinase-MB, PT=prothrombin time, Ig=immunoglobulin, IL=interleukin, C3=complement 3, C4=complement 4, CD=cluster of differentiation, NK= natural killer
Comparison between groups (P<0.05):AB= A compared with B, AC= A compared with C, AD=A compared with D, BC=B compared with C, BD=B compared with D, CD=C compared with D.

396 **Table 3. Features of study subjects based on presence of comorbidities**

	Have comorbidities (N=52)	Have no comorbidities (N=117)	p value
Disease severity- no./total no.(%)			0.004
Mild	1/52 (1.9)	11/117 (9.4)	0.108
Moderate	40/52 (76.9)	97/117 (82.9)	0.360
Severe	5/52 (9.6)	8/117 (6.8)	0.542
Critical	6/52 (11.6)	1/117 (0.9)	0.004
Sex - no./total no.(%)			0.368
Male	27/52 (51.9)	52/117 (44.4)	-
Female	25/52 (48.1)	65/117 (55.6)	-
Age in yrs- median (IQR)	59.88 (25–86)	48.69 (18–92)	0.001
Days from onset of illness to confirmation of diagnosis - median (IQR)	11.18 (0–40)	11.86 (0–45)	0.691
Symptoms - no./total no.(%)			
Fever	43/52 (82.7)	87/117 (74.4)	0.235
Dry cough	39/52 (75.0)	76/117 (68.0)	0.196
Sputum production	17/52 (33.3)	29/117 (24.8)	0.253
Shortness of breath	19/52 (36.5)	19/117 (16.2)	0.004
Digestive symptoms	6/52 (11.5)	9/117 (7.7)	0.604
Myalgia	9/52 (17.6)	20/117 (17.1)	0.931
Laboratory findings-median (IQR)			
SpO ₂ - %	94.4 (70–99)	96.3 (72–100)	0.121

Total protein - g/L	65.66 (39–84)	70.06 (36.7–98)	0.004
Albumin - g/L	36.34 (18–53)	39.9 (20–53.8)	0.002
Globulin - g/L	29.28 (18–47.2)	30.12 (9.8–54.5)	0.458
Total bilirubin - μmol/L	16.65 (4.3–62)	10.91 (2.7–49.2)	0.006
ALT-U/L	33.96 (2–120)	49.32 (10–574.7)	0.046
AST-U/L	38.94 (5–207)	44.54 (9–584)	0.476
GGT-U/L	71.33 (10–601)	81.99 (7–906)	0.706
Creatinine - μmol/L	81.69 (43–359)	69.45 (34.5–241)	0.177
White blood cell count - ×10⁹/L	7.74 (1.01–65)	6.77 (1.92–60.9)	0.404
Neutrophil count - ×10⁹/L	5.44 (0.52–20.71)	4.96 (0.8–55.6)	0.646
Lymphocyte count - ×10⁹/L	1.07 (0.18–2.66)	1.31 (0.26–4.11)	0.032
Hemoglobin - g/L	127.95 (84–191)	131.57 (100–230)	0.331
Platelet count - ×10⁹/L	213.34 (85–392)	226.73 (55–564)	0.292
C-reactive protein - mg/L	49.72 (0.3–254.35)	27.22 (0.04–285)	0.026
PCT -μg/mL	0.53 (0.02–6.02)	0.27 (0.02–1.74)	0.091
ESR - mm/h	44.67 (20–97.3)	37.62 (9–119)	0.175
LDH - U/L	327.21 (123–808)	235.51 (120–681)	0.002
Creatinekinase - U/L	106.45 (12–600)	107.91 (28–1381)	0.961
CK-MB - U/L	16.37 (5–73)	12.68 (1–45.7)	0.181
D-dimer -μg/ml	3.33 (0–80)	0.71 (0.01–8.00)	0.175
PT-s	18.18 (10.9–100)	13.22 (9.7–17.4)	0.101
Immunological findings- median (IQR)			

IgG- g/L	2.32 (1.37–3.54)	2.46 (1.32–5.09)	0.625
IgA- g/L	1.43 (0.46–2.98)	1.37 (0.38–3.15)	0.785
IgM- g/L	120.19 (0.8–1100)	99.05 (1.3–1008)	0.770
IgE- g/L	11.5 (7.24–16.88)	13.03 (7.42–20.81)	0.229
C3- g/L	0.91 (0.6–1.2)	0.93 (0.6–1.4)	0.719
C4- g/L	0.18 (0.1–0.3)	0.2 (0.1–0.4)	0.433
IL-6- pg/mL	17.67 (1.5–124.8)	23.42 (0–252.7)	0.773
CD3+ cell count - cell/μl	65.6 (58.64–75.45)	69.59 (47.77–86.66)	0.487
CD4+ cell count - cell/μl	12.48 (2.69–27.59)	8.9 (3.54–18.76)	0.379
CD8+ cell counts - cell/μl	14.99 (1.8–37.85)	17.61 (3.3–37.33)	0.673
CD4+ cell percentage - %	36.61 (10.83–59.3)	42.41 (31.23–55)	0.376
CD8+ cell percentage - %	26.85 (14.67–46.04)	28.8 (15.54–73.05)	0.816
Days before negative nucleic acid test-median (IQR)	8.18 (2–30)	6.16 (1–18)	0.092
Treatment - no./total no. (%)			
Antibiotics	33/52 (63.50)	58/117 (49.6)	0.095
Antiviral	49/52 (94.2)	105/117 (89.7)	0.558
Corticosteroids	16/52 (30.8)	32/117 (27.4)	0.649
Outcome - no./total no. (%)			0.008
Death	4/52 (7.7)	0/117 (0)	
Improvement	48/52 (92.3)	117/117 (100)	

397 IQR=interquartile range, ALT=alanine transaminase, AST=aspartate aminotransferase, GGT=gamma
398 glutamyl transferase, PCT=procalcitonin, LDH=lactate dehydrogenase, CK-MB=creatine kinase-MB,
399 ESR=erythrocyte sedimentation rate, PT=prothrombin time, Ig=immunoglobulin

Table 4: Relationship between age and disease severity (N=169)

Variable	B	Wald χ^2	P	95%CI
Q1	-4.604	32.983	0.000	(-6.175~-3.033)
Q2	0.512	0.586	0.444	(-0.799~1.823)
Q3	1.770	6.063	0.014	(0.361~3.180)
Age group (control: group 5)				
1	-2.675	8.098	0.004	(-4.518~-0.883)
2	-2.382	8.146	0.004	(-4.017~-0.746)
3	-1.768	5.022	0.025	(-3.314~-0.222)
4	-0.628	0.691	0.406	(-2.110~0.853)

Q1=Mild disease, Q2=Moderate disease, Q3=Severe disease, Q4=Critical disease

Age group (years, 15-year intervals): 1=18–32, 2=33–47, 3=48–62, 4=63–77, 5=78–92; B=regression

coefficient; OR=odds ratio; 95%CI=95% confidence interval

Table 5: Univariable and multivariable analyses of risk factors for disease severity (N=169)

Variable	Univariable analysis	Multivariable analysis		
	P	P	OR	95%CI
SpO ₂ (%)	0.000	0.000	0.693	(0.572–0.839)
Age(Year)	0.003	0.482	-	-
Lymphocytes($\times 10^9/L$)	0.000	0.047	0.176	(0.032–0.976)
CRP rise(No)	0.003	0.212	-	-
LDH rise(No)	0.002	0.974	-	-
Administration of corticosteroids	0.000	0.505	-	-
Days from onset of illness to confirmation of	0.049	0.070	-	-

diagnosis time				
Underlying disease(No)	0.043	0.185	-	
Albumin (g/L)	0.002	-	-	-
D-dimer (μg/ml)	0.019	0.307	1.056	(0.951–1.171)
Dyspnea(No)	0.000	0.270	-	-
Cough(No)	0.032	-	-	-

LDH=lactate dehydrogenase; CRP=C-reactive protein; OR=odds ratio; 95%CI=95% confidence interval

Table6: Chest CT findings of study subjects on different days*

	On admission	Group1(≤7 days)	Group2(8–14 days)	Group3(15–21days)	Group4(22–28days)	Group5(29–45 days)	Group6(46–60days)	p value
Number of patients	116	59	92	109	60	52	18	
Days from onset of illness to chest CT-median (IQR)	10.73±7.97 (0-34)	4.610±2.14 (0-7)	11.09±1.93 (8-14)	17.72±2.01 (15-21)	24.98±1.92 (22-28)	34.58±5.18 (29-45)	51.72±3.64 (45-57)	
Bilateral lung involvement - no./total no.(%)	84/116 (72.4)	39/59 (66.1)	68/92 (73.9)	87/109 (79.8)	51/60 (85)	39/52 (75)	12/18 (66.7)	0.158
Distribution of lesions in lung-no./total no.(%)								
Peripheral	88/116(75.86)	41/59 (69.49)	72/92 (78.26)	92/109 (84.40)	55/60 (91.67)	47/52 (90.38)	17/18 (94.44)	0.006
Along the bronchi	30/116(25.86)	10/59 (16.95)	32/92 (34.78)	33/109 (30.28)	12/60 (20.00)	11/52 (21.15)	2/18 (11.11)	0.049
Random	3/116 (2.59)	4/59 (6.78)	2/92 (2.17)	1/109 (0.92)	0/60 (0)	0/52 (0)	0/18 (0)	0.101
Diffuse	11/116 (9.48)	4/59 (6.78)	6/92 (6.52)	9/109 (8.26)	2/60 (3.33)	1/52 (1.92)	1/18 (5.56)	0.638
CT								

findings-no./total no.(%)								
Ground-glass opacity	64/116(55.2)	48/59(81.4)	48/92(52.2)	41/109(37.6)	17/60(28.3)	19/52(36.5)	8/18(44.4)	0.001#
Consolidation	77/116(66.4)	30/59(50.9)	72/92(78.3)	80/109(73.4)	37/60(61.7)	33/55(63.6)	14/18(77.8)	0.004@
Ground-glass opacity with consolidation	39/116(33.6)	16/59(27.1)	31/92(33.7)	34/109(31.2)	12/60(20.0)	16/55(29.1)	6/18(33.3)	0.337
Linear opacity	64/116(55.2)	20/59(33.9)	53/92(57.6)	91/109(83.5)	56/60(93.3)	51/52(98.1)	18/18(100)	0.001
Reticular change	15/116(12.93)	4/59(6.78)	5/92 (5.43)	18/109 (16.51)	13/60 (21.67)	13/52 (25.00)	7/18 (38.89)	0.001 ¥
Pleural thickening	6/116 (5.17)	0/59 (0)	3/92 (3.26)	9/109 (8.26)	7/60 (11.67)	9/52 (17.31)	3/18 (16.67)	0.001
Pleural effusion	2/116 (1.72)	1/59 (1.69)	0/92 (0)	2/109 (1.83)	1/60 (1.67)	1/52 (1.92)	0/18 (0)	0.753
Vascular thickening		12/59	28/92	47/109		32/52	6/18	
	40/116(34.48)	(20.34)	(30.43)	(43.12)	25/60 (41.67)	(61.54)	(33.33)	0.001
Number of lung lobes involved-no./total no.(%)								
		20/59	43/92	58/109		28/52	12/18	
5	56/116(48.28)	(33.90)	(46.74)	(53.21)	33/60 (55.00)	(53.85)	(66.67)	0.079

		6/59	7/92	14/109		7/52		
4	10/116(8.662)	(10.17)	(7.61)	(12.84)	6/60 (10.00)	(13.46)	0/18 (0)	0.530
		10/59	11/92	9/109	4/60	11/52	6/18	
3	16/116(13.79)	(16.95)	(11.96)	(8.26)	(6.67)	(21.15)	(33.33)	0.011
		12/59	20/92	18/109		4/52		
2	17/116(14.66)	(20.34)	(21.74)	(16.51)	12/60 (20.00)	(7.69)	0/18 (0)	0.100
		11/59	11/92	10/109	5/60	2/52		
1	17/116(14.66)	(18.64)	(11.96)	(9.17)	(8.33)	(3.85)	0/18 (0)	0.083

* Days from onset of illness to chest CT examination

CT=computed tomography, IQR=interquartile range

#: Group1 compared to other groups; Group2 compared to Group3 and Group4; p<0.05

@: Group1 compared toGroup2, Group3, and Group4; Group2 compared toGroup5; p<0.05

¥ : Group1 compared to other groups; Group2 compared to other groups; p<0.05

Table 7: Univariable and multivariable analysis of factors associated with the time it takes for nucleic acid test to turn negative (N=79)

Variable	Univariable analysis	Multivariable analysis		
	P	P	B	95%CI
Sex(Male)	0.079	-	-	-
Age(Year)	0.278	-	-	-
Lymphocytes($\times 10^9/L$)	0.005	0.014	-2.974	(-5.327~-0.620)
CRP(mg/L)	0.021	0.954	0.001	(-0.022~0.024)
LDH(U/L)	0.005	0.730	0.003	(-0.012~0.017)
Corticosteroids	0.005	0.137	-1.710	(-3.978~0.557)
Antibiotics	0.024	0.154	-1.563	(-3.723~0.598)

LDH=lactate dehydrogenase; CRP=C-reactive protein; B=Regression coefficients; 95%CI=95% confidence interval

Table 8: Univariable and multivariable analysis of factors associated with the time it takes for symptoms to improve (N=53)

Variable	Univariable analysis	Multivariable analysis		
	P	P	B	95%CI
Sex(Male)	0.724	-	-	-
Age(Year)	0.052	0.095	0.146	(-0.025~0.319)
Lymphocytes($\times 10^9/L$)	0.029	0.440	1.713	(-2.708~6.134)
CRP(mg/L)	0.993	-	-	-
LDH(μ/L)	0.792	-	-	-
Administration of corticosteroid	0.323	-	-	-
Time from onset of illness to confirmation of diagnosis (days)	0.000	0.001	0.527	(0.219~0.835)

LDH=lactate dehydrogenase; CRP=C-reactive protein; B=Regression coefficients; 95%CI=95% confidence interval

Table 9:Univariable and multivariable analysis of factors associated with chest CT improvement(N=62)

Variable	Univariable analysis	Multivariable analysis		
	P	P	HR	95%CI
Sex(Male)	0.023	0.109	0.608	(0.331–1.117)
Age(Year)	0.195	-	-	-
Lymphocytes($\times 10^9/L$)	0.088	0.278	1.374	(0.774–2.440)
CRP(mg/L)	0.561	-	-	-
LDH(U/L)	0.899	-	-	-
Administration of corticosteroid	0.540	-	-	-
Time from onset of illness to confirmation of diagnosis (days)	0.075	0.013	1.019	(1.019–1.168)
Disease severity	0.045	0.061	-	-
Moderate(compared to mild mild)	-	0.008	0.261	(0.097–0.704)
Severe(compared to mild mild)	-	0.057	0.192	(0.035–1.049)
Critical(compared to mild mild)	-	0.971	0	0
Time of onset to nucleic acid positive time(days)	0.059	0.853	1.009	(0.918–1.110)

CT=computed tomography, LDH=lactate dehydrogenase, CRP=C-reactive protein, HR=hazard ratio, 95%CI=95% confidence interval

Figurelegends

Figure 1 : Computed tomography findings in the lungs on different days in the course of the disease in a patient with severe disease.(a)4 days from onset of illness.(b)8 days from illness onset (patient's clinical symptoms began to improve) .(c)13 days from onset of illness. (d)18 days from onset of illness. (e)23 days from onset of illness onset.

Figure 2: Computed tomography findings in the lungs on different days in the course

of the disease in a patient with moderate disease. (a)5 days from onset of illness. (b)10 days from onset of illness (patient's clinical symptoms began to improve). (c)15 days from onset of illness. (d)21 days from onset of illness.

Figure 3: Correlations between: The days of nucleic acid test turned negative and lymphocytes;

Figure 4: Correlations between: Time from onset of symptoms to confirmation of diagnosis and Time it took for symptoms to improve.